Illumina, Inc. (NASDAQ:ILMN) Shares Bought by 180 Wealth Advisors LLC

180 Wealth Advisors LLC grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 112.2% during the second quarter, Holdings Channel.com reports. The firm owned 4,323 shares of the life sciences company’s stock after buying an additional 2,286 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Illumina were worth $813,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Polen Capital Management LLC raised its position in shares of Illumina by 11.7% during the 4th quarter. Polen Capital Management LLC now owns 5,048,402 shares of the life sciences company’s stock worth $1,020,787,000 after buying an additional 527,005 shares in the last quarter. Alliancebernstein L.P. raised its position in Illumina by 145.8% in the fourth quarter. Alliancebernstein L.P. now owns 3,869,403 shares of the life sciences company’s stock worth $782,393,000 after acquiring an additional 2,294,942 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Illumina by 1.9% in the 1st quarter. Geode Capital Management LLC now owns 2,928,326 shares of the life sciences company’s stock worth $679,269,000 after purchasing an additional 54,951 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Illumina by 268.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,113,230 shares of the life sciences company’s stock valued at $427,295,000 after buying an additional 1,539,186 shares in the last quarter. Finally, Select Equity Group L.P. boosted its stake in shares of Illumina by 22.5% during the 4th quarter. Select Equity Group L.P. now owns 1,912,714 shares of the life sciences company’s stock worth $386,751,000 after acquiring an additional 351,701 shares in the last quarter. 92.17% of the stock is currently owned by institutional investors.

Insider Activity at Illumina

In other Illumina news, SVP Susan H. Tousi sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $200.00, for a total value of $100,000.00. Following the sale, the senior vice president now owns 46,522 shares of the company’s stock, valued at approximately $9,304,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 1,500 shares of company stock worth $278,560 in the last 90 days. 0.13% of the stock is owned by company insiders.

Illumina Price Performance

Shares of Illumina stock opened at $142.41 on Tuesday. Illumina, Inc. has a 1-year low of $142.00 and a 1-year high of $248.87. The firm has a fifty day simple moving average of $174.51 and a 200-day simple moving average of $197.05. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.13 and a current ratio of 1.40.

Illumina (NASDAQ:ILMN) last released its earnings results on Wednesday, August 9th. The life sciences company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.30. The firm had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.16 billion. Illumina had a negative net margin of 93.86% and a positive return on equity of 1.97%. The business’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.57 EPS. As a group, research analysts expect that Illumina, Inc. will post 0.83 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on ILMN. Credit Suisse Group reduced their price objective on shares of Illumina from $225.00 to $200.00 and set a “neutral” rating for the company in a research note on Thursday, August 10th. JPMorgan Chase & Co. dropped their price target on Illumina from $235.00 to $190.00 and set a “neutral” rating on the stock in a research report on Thursday, August 10th. Royal Bank of Canada lowered their target price on Illumina from $337.00 to $328.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 8th. HSBC reduced their price target on shares of Illumina from $270.00 to $235.00 and set a “buy” rating for the company in a research report on Monday, August 14th. Finally, Piper Sandler dropped their price objective on shares of Illumina from $290.00 to $275.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $236.05.

Illumina Profile

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.